
Hepatitis C: State of Medicaid Access Report Card

Tennessee



Grade	Recommendations to Improve Patient Access		
В	 Remove prior authorization for HCV treatment. Remove retreatment restrictions. Remove additional restrictions as described below. 		

State Overview

As of February 2022, 1,698,810 individuals were enrolled in Medicaid and CHIP.¹ It is estimated that as of 2016, 69,100 people were living with HCV in Tennessee.² Tennessee Medicaid contracts with three managed care organizations (MCOs): Amerigroup, BlueCare, and UnitedHealthcare Community Plan.³

The Tennessee Medicaid Preferred Drug List includes Epclusa (brand and generic), Harvoni (brand and generic), and Mavyret.4

Deductions		Policy		
Prior Authorization	-8	Prior authorization is required for all Direct-Acting Antiviral (DAA) HCV treatment regimens. ⁵		
Fibrosis Restrictions		Tennessee Medicaid does not impose fibrosis restrictions. ⁶		
Substance Use Restrictions		Tennessee Medicaid does not impose substance use restrictions. ⁷		
Prescriber Restrictions		Tennessee Medicaid does not impose prescriber restrictions. Primary care physicians can lead treatment alone unless patients have "a history of HIV, HBC co-infection, prior history with direct acting hepatitis C antivirals, or decompensated cirrhosis" or "authorization is being requested by or in consultation with a physician specialist with experience in the treatment of hepatitis C infection (e.g., Hepatology, Infectious Disease or Gastroenterology)."		
Retreatment Restrictions		Tennessee Medicaid does not impose retreatment restrictions. ⁹		
Access in Managed Care		Amerigroup, BlueCare, and UnitedHealthcare Community Plan impose the same requirements as FFS. Optum Rx is the pharmacy benefit manager for all MCOs, providing the same coverage across the state's Medicaid program. ¹⁰		
Additional Restrictions	-4	Tennessee Medicaid imposes additional restrictions as follows: ¹¹		
Total Deductions		Total Score [100-Deductions]	Grade	
-12		88	В	

Contact Your State Officials

Medicaid Office¹²: Stephen Smith, Deputy Commissioner and Director of TennCare 310 Great Circle Road, Nashville, TN 37243; Telephone: (800) 342-3145; Email Address: Tenn.Care@tn.gov

Key Sources

Preferred Drug List: TennCare, PDL (May 2022).

Clinical Criteria: TennCare, Clinical Criteria, Step Therapy, and Quantity Limits for TennCare Preferred Drug List (PDL) (May 2022).

Prior Authorization Form: TennCare, Prior Authorization Form (Mar. 2022).





- ¹ Centers for Medicare & Medicaid Services, Medicaid & CHIP in Tennessee: https://perma.cc/XX7U-XTTR.
- ² HepVu, Local Data: Tennessee (Jan. 2022): https://perma.cc/34US-H34S.
- ³ Division of TennCare, Managed Care Organizations: https://perma.cc/9KPR-D4VS.
- ⁴ Preferred Drug List.
- ⁵ Preferred Drug List.
- ⁶ Clinical Criteria.
- ⁷ Prior Authorization Form.
- ⁸ Clinical Criteria.
- ⁹ Clinical Criteria.
- ¹⁰ Division of TennCare, Prescriber (May 2022): https://perma.cc/H2DY-W9H6.
- ¹¹ TennCare, Prior Authorization Form (Mar. 2022): https://perma.cc/9L7P-V4DH.
- ¹² National Association of Medicaid Directors, Medicaid Directors: https://perma.cc/RK6K-TFKK.



